Scientists at Lazzaro Spallanzani National Institute for Infectious Diseases in Italy have claimed that a vaccine candidate could neutralise coronavirus within human cells.

According to findings from the tests conducted at Spallanzani Hospital in Rome, the vaccine generated antibodies in mice that work on human cells.

These antibodies were observed to prevent the virus from infecting the cells.

Takis Biotech is the company developing the coronavirus vaccine candidate.

An Italian news agency, ANSA, quoted Takis Biotech CEO Luigi Aurisicchio as saying: “This is the most advanced stage of testing of a candidate vaccine created in Italy. Human tests are expected after this summer.”

Takis was allegedly exploring options with US-based LineaRx. However, the company requires the Italian government’s support and alliances with international bodies to further develop the vaccine, added Aurisicchio.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Aurisicchio also noted: “This is not a competition. If we join our forces and skills together, we can all win against coronavirus.”

Of the five vaccine candidates that produced a large number of antibodies, the researchers selected two. All of the candidates being developed are based on the genetic material of DNA protein ‘spike’.

Currently, scientists are studying the longevity of the vaccine’s immunity response.

The vaccine uses a technique called electroporation to help break into the cells and induce the immune system.

According to the researchers, this mechanism is expected to boost the vaccine’s effectiveness in producing functional antibodies against ‘spike’ protein in lung cells.

In addition, Takis infectious diseases area director Dr Emanuele Marra said that the vaccines have the potential for adapting to any future mutations of the virus.

In March, Takis secured approval from the Ministry of Health in Italy for preclinical testing of its Covid-19 vaccine.

The company and its partner Applied DNA Sciences announced the design of four coronavirus vaccine candidates earlier in March.